Italia markets closed

Zealand Pharma A/S (0NZU.IL)

IOB - IOB Prezzo differito. Valuta in DKK.
Aggiungi a portafoglio
131,75-7,70 (-5,52%)
Alla chiusura: 05:32PM GMT
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

    Company announcement – No. 3 / 2022 Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome Full trial results of EASE-SBS 1 expected in the third quarter of 2022Pending positive pivotal data, Zealand intends to file for marketing approval with the U.S. Food and Drug Administration Copenhagen, DK and Boston, MA, U.S. January 20, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the

  • GlobeNewswire

    Zealand Pharma major shareholder announcement: The Capital Group Companies, January 2022

    Company announcement – No. 2 / 2021 Zealand Pharma major shareholder announcement: The Capital Group Companies, January 2022 Copenhagen, DK and Boston, MA, January 19, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareho

  • GlobeNewswire

    Zealand Pharma to Participate in H.C. Wainwright BIOCONNECT 2022 Conference

    Company announcement – No. 1 / 2022 Zealand Pharma to Participate in H.C. Wainwright BIOCONNECT 2022 Conference Copenhagen, DK and Boston, MA, U.S. January 3, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate in the H.C. Wainwright BIOCONNECT 2022 Conference: H.C. Wainwright BI